# BPC-157 FAQ: Safety, Timing, Routes, and Common Questions > BPC-157 questions answered from the research: does it work, is it safe for the liver, kidneys, and heart, how it compares to TB-500, how long it takes, and its FDA 503A status. Direct answers to the twenty-five questions people most often ask about BPC-157 — efficacy, safety, timing, routes, comparisons, and regulatory status — each tied to the published record. ## Is BPC-157 a growth hormone? No. BPC-157 is a 15-amino-acid gastric pentadecapeptide, not a growth hormone or any hormone. It has no endogenous circulating pool. It is reported to up-regulate the growth-hormone receptor in tendon fibroblasts [1], which is a receptor-level effect, not evidence that the peptide is itself a hormone. ## Does BPC-157 work immediately? No. Animal studies dose BPC-157 once daily over days to weeks and measure outcomes across a healing course, not within minutes [1]. Its elimination half-life in animals is under `30 min` [2], so any sustained effect is a tissue-repair process over time rather than an immediate sensation. ## Does BPC-157 damage the liver? No liver damage was reported in the available human data: the 2025 IV pilot in two adults found no measurable changes in hepatic biomarkers [5]. Rat work even reports protection of the liver in injury models [11]. Long-term human liver safety, however, is unknown given how small the dataset is [6]. ## Is BPC-157 hard on the kidneys? The same two-adult IV pilot found no measurable renal-biomarker changes [5], and rat pancreatitis work reports reduced kidney injury [11]. There are no large human safety data, so "hard on the kidneys" cannot be confirmed or ruled out beyond this very small evidence base [6]. ## Can BPC-157 mess with your heart? The IV human pilot reported no measurable cardiac-biomarker changes in two adults [5], and rat models report cardioprotective effects. The human cardiac-safety profile remains unestablished, because two people is far too small a sample to characterize cardiac effects [6]. ## Is BPC-157 bad for the heart? Available evidence — a two-person IV pilot [5] and rodent cardiac models — shows no signal of cardiac harm. The dataset is too small to establish human cardiac safety either way, so this is an absence of evidence of harm, not evidence of safety [6]. ## Can BPC-157 cause liver damage? No liver damage was observed in the two-adult IV pilot [5], and rat studies report hepatoprotection in injury models [11]. Long-term human liver-safety data are absent, so the possibility of liver effects with extended use cannot be excluded from the current literature [6]. ## What happens when you stop taking BPC-157? Discontinuation effects are not characterized in humans. Only short pilot exposures have been studied — a single intravesical dose [8], a brief IV infusion in two adults [5] — so there is no published account of what follows stopping BPC-157 in people. ## What should you not mix with BPC-157? Rodent work studies BPC-157 as a counter-agent to NSAID injury, including diclofenac models, rather than as something taken alongside drugs. No human interaction data exist to establish what to avoid, so any specific combination guidance would go beyond the published evidence. ## How does BPC-157 make you feel? Subjective human experience is not formally measured in the BPC-157 literature. The two-adult IV pilot reported good tolerability with no adverse events [5], but it did not capture a subjective "how it feels" outcome, so there is no validated description of felt effects. ## How long does BPC-157 take to work? Animal tendon and ulcer studies measure healing over days to weeks of daily dosing [1][4], not hours. No human time-to-effect has been established, so any timeline applied to a person is an extrapolation from the fixed-duration preclinical designs rather than a measured human result. ## How long does it take for BPC-157 to kick in? There is no validated human onset time for BPC-157. In preclinical models, effects accrue over a multi-day healing course rather than appearing acutely [1]. The short animal half-life of under `30 min` [2] means any lasting effect reflects tissue repair over time, not a rapid onset. ## Can BPC-157 help with weight loss? Published evidence does not support weight loss. Common online metabolic claims for BPC-157 — weight loss, muscle building, testosterone increase — are not backed by the literature and should be treated skeptically [6]. The studied effects center on tissue protection and repair, not body composition. ## What does BPC-157 do in the body? In animal models BPC-157 acts as a cytoprotective peptide, promoting tissue repair largely through angiogenesis — new blood-vessel growth — via VEGFR2-Akt-eNOS signaling [3]. Reported secondary routes include the FAK-paxillin pathway and growth-hormone-receptor sensitization in tendon fibroblasts. These are preclinical descriptions of mechanism, detailed further on the [research](/research) page. ## Does BPC-157 really work? Most BPC-157 evidence is preclinical, so human efficacy is unestablished. A 2025 narrative review found only three small human pilot studies and concluded rigorous large-scale trials are lacking [6]. The animal recovery data are large and reproducible [1][4], but reproducibility in rodents does not prove a human effect. ## Has anyone used BPC-157 to heal an injury? Published human use is limited to small uncontrolled pilots: an intra-articular case series reported reduced knee pain across several pain types [7], and a 12-patient intravesical pilot reported interstitial-cystitis symptom improvement [8]. Neither had a comparator group, so they signal feasibility rather than proven injury-healing in people. ## Is BPC-157 worth it for tendon recovery? Animal Achilles-tendon work shows accelerated, well-organized healing at doses near `10 microg/kg` in rats [1], but human tendon-recovery evidence is anecdotal. No controlled human tendon trial of BPC-157 exists, so any "worth it" judgment for a person is made without clinical efficacy data. ## Can BPC-157 heal arthritis? An uncontrolled human case series reported improvement across multiple types of knee pain after intra-articular BPC-157 [7]. That is a preliminary symptom signal, not controlled arthritis-efficacy evidence — no comparator group and no structural-outcome measure — so it cannot establish that BPC-157 heals arthritis. ## Can BPC-157 be taken orally? BPC-157 is described as stable in gastric juice, which motivates oral interest, and several rodent GI studies dose it intragastrically with measurable effect [4]. But formal human oral pharmacokinetics have not been characterized [2], so whether an oral dose reaches systemic circulation in people at a meaningful level is unknown. ## Does oral BPC-157 work? Some rodent gastrointestinal studies use intragastric or peroral BPC-157 and report effect, particularly on gut tissue [4]. Oral human bioavailability, however, is not characterized — the animal-PK work measured intravenous and intramuscular routes [2] — so "works orally in humans" is not something the published evidence can confirm. ## What does the latest BPC-157 research say? Recent 2024-2026 work reinforces interest while underscoring the human-data gap: a 2025 IV safety pilot in two adults [5], a 2024 interstitial-cystitis pilot [8], and rat studies reporting distant-organ protection in acute pancreatitis [11] and a tracheocutaneous-fistula resolution via the NO system [10]. A 2025 review still calls the molecule investigational [6]. ## How long should I stay on BPC-157? Animal studies use defined dosing courses over days to weeks, not open-ended use, and there is no validated human protocol [6]. A 2025 review urges treating BPC-157 as investigational [6], so "how long to stay on it" has no evidence-based answer for a person — only the fixed-duration designs of the preclinical studies. ## BPC-157 vs TB-500 in the Literature BPC-157 and TB-500 (a thymosin beta-4 fragment) are different peptides studied in overlapping tissue-repair contexts, and this site documents only BPC-157. BPC-157's repair signal is tied to VEGFR2-Akt-eNOS angiogenesis [3]; TB-500's literature centers on actin regulation and cell migration. Both are research peptides without large controlled human efficacy trials, and both sit in the same FDA 503A category discussed on the [BPC-157 legal status](/legal-status) page. Direct head-to-head human comparisons do not exist in the published record. ## Is BPC-157 legal? BPC-157 is not an FDA-approved drug. The [FDA 503A compounding status](/legal-status) page covers the specifics: FDA placed BPC-157 in a 503A category identified as potentially presenting significant safety risks, and it is prohibited in sport by WADA. Legality depends on jurisdiction and context, so see that page for the regulatory picture. ## Can you get BPC-157 from a compounding pharmacy? Not through routine 503A compounding while its current status stands. FDA placed BPC-157 in Category 2 — bulk substances identified as potentially presenting significant safety risks — effective with its September 29, 2023 nominated-substances update, which is outside FDA's enforcement-discretion policy for 503A compounding. The [legal status](/legal-status) page explains the pathway in full. ## What is the FDA 503A status of BPC-157? FDA placed BPC-157 (the entries "BPC-157 (free base)" and "BPC-157 acetate") in 503A Category 2 — bulk drug substances that may present significant safety risks — effective with its September 29, 2023 update, so it is not within FDA's enforcement-discretion policy for compounding. BPC-157 is also on the published agenda of the July 23-24, 2026 PCAC meeting as a substance being considered for the 503A Bulks List; that is a scheduled discussion, not a decision. Full detail is on the [legal status](/legal-status) page. --- A two-tier readout of the BPC-157 record — the human pilots logged above the animal evidence, sourced line by line, with no clinic behind the console and nothing here for sale.